New drug cocktail aims to fight rare lymphoma without chemo
NCT ID NCT07299331
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 26 times
Summary
This study tests whether a combination of three drugs (zanubrutinib, rituximab, and lenalidomide) can effectively treat marginal zone lymphoma in people who have not received prior therapy. About 50 adults aged 18-75 with advanced-stage disease will take the drugs and be monitored regularly. The goal is to see if this approach improves survival and has manageable side effects compared to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.